Biocryst Pharma Inc (BCRX) Stock Price, Quote & News

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 919 859 1302

Fax: 919 859 1314

Website: www.biocryst.com

Address:

4505 Emperor Boulevard, Suite 200, Durham, United States

Happy_Dough_Boy Aug. 3 at 3:10 AM

$BCRX Just thinking about the Stonehouse retirement. It makes sense earnings should go well, since they’ve already announced Charlie will be the CEO. That way, at the ER call, Jon can acknowledge Charlie’s success launching and building sales for Orladeyo, then celebrate his upcoming promotion to CEO. I do admit, I’m a forever optimist for BCRX.

0 · Reply

maphere Aug. 2 at 8:12 PM

$BCRX $CLSD Dot connecting: CLSD slide deck (7/25): Undisclosed Therapeutic Modulate pro-inflammatory cells Geographic Atrophy (GA) BCRX 10-Q (3/2025): Bifunctional Complement Inhibitor. We are developing a bifunctional complement inhibitor anti-C2 monoclonal antibody that could be a first-inclass combined inhibitor of the classical, lectin and alternative pathways of the complement system to treat complex complement-mediated diseases that are influenced by multiple complement pathways. Google A.I.: Pro-inflammatory cells and bifunctional inhibitors Future outlook Research into bifunctional complement inhibitors and therapies that target multiple aspects of the inflammatory response holds the potential to significantly improve the treatment of GA. The goal is to develop therapies that not only slow the progression of GA but also preserve visual function and minimize adverse effects, thereby enhancing the quality of life for individuals affected by this debilitating disease.

4 · Reply

Ttubular Aug. 2 at 7:02 PM

$BCRX excited for Monday

1 · Reply

maphere Aug. 2 at 4:21 PM

$BCRX $CLSD Predictions after the fact don't mean much...so here I go. BCRX acquires CLSD gaining their patents, microinjector and future revenue streams from the existing partners (RGNX, BLCO, AURA, Arctic and themselves), and pays off their debt. BCRX doses DME patient after the BO to avoid a milestone payment. BCRX went into the DME program with a high level of confidence of drug sustainability (up to 6 months) using the SCS injector. CLSD has 2 undisclosed molecules for GA. They are presenting NEW DATA in Dec., based on a brochure download, see below. I think the molecules belong to BCRX, I've been told directly by XXX that BCRX has a "stable of molecules." If GA (aka DryAMD) is a real target for BCRX then it's bigger than anything they've touched so far...it's the Holy Grail for eye disease and worthy of what would be considered a small investment for a BO if they move forward. CLSD has cleaned out the cupboard for new management and hired Piper to make a deal. This is my prediciton.

7 · Reply

trustbutverify Aug. 2 at 1:03 PM

$BCRX Monday’s key: BCRX needs to meet revenue, but more importantly, beat on profitability. If margins improve, the stock should react. Also watching for updates on pediatric Orladeyo and Netherton Syndrome. Those 3 are key to me.

0 · Reply

Ttubular Aug. 2 at 12:37 PM

$BCRX the way I read yesterday’s action is that every time it tried to go up it got shorted hard to keep it down. So the big boys tried hard to keep shorting it hard on heavy volume on every move up to steal shares. So I’m thinking something good is coming soon to BCRX. So let’s hope that was what yesterday’s action was. IMHO

3 · Reply

US_Bull Aug. 2 at 11:50 AM

$BCRX Additional bullish signals: 1. 8$ strikes, bid is 0.45 and ask is 0.90 2. 8$ puts, bid is 0.50 and ask is 2.35 even though they are currently in the money. In other words, the calls strikes are met easier than the put strikes. 3. Volume has been excessive past few trading days and the biosector especially with tariffs has been trading like crap. Stock has been trading on par with other bios based on heavy volume. If that volume was mostly sell volume stock would have been expected to be trading far below compared to other bios.

1 · Reply

US_Bull Aug. 2 at 11:31 AM

$BCRX Downside risk vs. upside risk is tilted towards the latter. You don't get another >30% haircut due to the fact that stock has been artificially walked down already the past few weeks on no news. However upside risk for short sellers is far greater. Option market does however not see a great move to either side. Cautiously optimistic I think we see a closer move towards 9$ after this week.

1 · Reply

SNOB_ORDER Aug. 2 at 10:40 AM

$BCRX ....wrong ....

0 · Reply

Ttubular Aug. 2 at 10:38 AM

$BCRX wow now #1!!!!!! Monday will be great. Imagine if we get BO PR instead of earnings. Then it’s $16+

0 · Reply

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 21, 2025, 7:00 AM EDT - 12 days ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 24 days ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 7, 2025, 7:00 AM EDT - 26 days ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jul 3, 2025, 7:00 AM EDT - 4 weeks ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 27, 2025, 7:00 AM EDT - 5 weeks ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 16, 2025, 7:00 AM EDT - 6 weeks ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 13, 2025, 7:00 AM EDT - 7 weeks ago

ORLADEYO® (berotralstat) Approved in Colombia

Jun 6, 2025, 7:00 AM EDT - 2 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 2, 2025, 7:00 AM EDT - 2 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

May 30, 2025, 7:00 AM EDT - 2 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 27, 2025, 7:00 AM EDT - 2 months ago

BioCryst to Present at Upcoming Investor Conferences

May 16, 2025, 7:00 AM EDT - 2 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 14, 2025, 7:00 AM EDT - 2 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 5, 2025, 5:29 PM EDT - 3 months ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 2:05 PM EDT - 3 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 12:54 PM EDT - 3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 7:00 AM EDT - 3 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 3 months ago

BioCryst Appoints Steve Frank to Board of Directors

Apr 21, 2025, 7:00 AM EDT - 3 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 2, 2025, 4:01 PM EDT - 4 months ago

BioCryst to Present at Upcoming Investor Conference

Feb 26, 2025, 9:09 AM EST - 5 months ago

BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 7:45 AM EST - 5 months ago

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

Feb 25, 2025, 6:24 PM EST - 5 months ago

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Feb 24, 2025, 12:17 PM EST - 5 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 11:49 AM EST - 5 months ago

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Feb 24, 2025, 7:00 AM EST - 5 months ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 6:00 AM EST - 5 months ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

Feb 12, 2025, 7:00 AM EST - 6 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 10, 2025, 8:30 AM EST - 6 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 7:00 AM EST - 6 months ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Jan 10, 2025, 7:00 AM EST - 7 months ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 7, 2025, 7:00 AM EST - 7 months ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 1:47 PM EST - 8 months ago

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Nov 18, 2024, 2:00 AM EST - 9 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

Nov 4, 2024, 11:00 AM EST - 9 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

Oct 21, 2024, 7:00 AM EDT - 10 months ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

Oct 14, 2024, 7:00 AM EDT - 10 months ago

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Oct 2, 2024, 7:00 AM EDT - 10 months ago

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Sep 30, 2024, 7:00 AM EDT - 10 months ago

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

Sep 17, 2024, 7:00 AM EDT - 11 months ago

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

Sep 6, 2024, 2:00 AM EDT - 11 months ago

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

Aug 5, 2024, 11:44 AM EDT - 1 year ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 7:00 AM EDT - 1 year ago

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 7:00 AM EDT - 1 year ago

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Jul 21, 2024, 7:30 AM EDT - 1 year ago

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 9, 2024, 7:00 AM EDT - 1 year ago

ORLADEYO® (berotralstat) Approved in Peru

Jun 2, 2024, 4:00 AM EDT - 1 year ago

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

May 14, 2024, 7:00 AM EDT - 1 year ago

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

May 13, 2024, 7:00 AM EDT - 1 year ago

ORLADEYO® (berotralstat) Approved in Mexico

Happy_Dough_Boy Aug. 3 at 3:10 AM

0 · Reply

maphere Aug. 2 at 8:12 PM

4 · Reply

Ttubular Aug. 2 at 7:02 PM

$BCRX excited for Monday

1 · Reply

maphere Aug. 2 at 4:21 PM

7 · Reply

trustbutverify Aug. 2 at 1:03 PM

0 · Reply

Ttubular Aug. 2 at 12:37 PM

3 · Reply

US_Bull Aug. 2 at 11:50 AM

1 · Reply

US_Bull Aug. 2 at 11:31 AM

1 · Reply

SNOB_ORDER Aug. 2 at 10:40 AM

$BCRX ....wrong ....

0 · Reply

Ttubular Aug. 2 at 10:38 AM

$BCRX wow now #1!!!!!! Monday will be great. Imagine if we get BO PR instead of earnings. Then it’s $16+

0 · Reply

Ttubular Aug. 2 at 10:30 AM

$BCRX wow trending #2 on a Saturday!!! Here comes $11+

0 · Reply

SNOB_ORDER Aug. 2 at 10:24 AM

$BCRX Where BCRX was and where is going .... (2021--->...........)

1 · Reply

SNOB_ORDER Aug. 2 at 10:04 AM

$BCRX The history tells us, Q2 beats Q1 .... EPS Q1 $0,00 SP $7,50 EOQ -- Short Interest 20,727,104 EOQ -- $11,03 ER Q1 EOD EPS Q2 $... SP $8,96 EOQ -- Short Interest 27,224,168, -- $??,?? ER Q2 EOD ....and we could see more than 1 PR Monday (IMO)

2 · Reply

Surgemono Aug. 2 at 9:44 AM

$BCRX of course pure speculation but prior the BO usually company stock is being pulled down to shake retail off. it just feels odd here. We been going down for quite sometime. 🤔

1 · Reply

steven1x Aug. 2 at 2:26 AM

$BCRX https://finance.yahoo.com/news/biocryst-pharmaceuticals-q2-earnings-play-171200401.html

0 · Reply

US_Bull Aug. 1 at 10:27 PM

$BCRX Finally note the option market looking at 8,00$ strike calls vs. puts there is much less volatility on the call side and the bid is closer to be met by the ask price. Puts just the opposite even though currently 8,00$ puts are in the money. Very bullish GL shortie you are gonna need it big time imo.

1 · Reply

Ttubular Aug. 1 at 9:55 PM

$BCRX everyone have a great weekend. Don’t worry about today our day will be Monday.

0 · Reply

US_Bull Aug. 1 at 9:15 PM

$BCRX The fact that they have put ER on a monday morning makes confident that numbers should be ok, as the stock can run the whole week. On the other hand, if they had scheduled it for Thursday or Friday just the opposite from my previous experience. Also the fact that Takeda's growth has gone down those numbers have to be compensated by something else. Also volume was very high today and stock ended in the red comparable to many other stocks. All very bullish imo. We are gonna find out first thing Monday morning.

2 · Reply

BirdStar Aug. 1 at 8:55 PM

$BCRX See you guys on Monday. May fortune favor the bold, and stubborn.

0 · Reply

Money_Mane Aug. 1 at 8:25 PM

$BCRX what are the chances they announce they bought clearside Monday?

6 · Reply

Ttubular Aug. 1 at 8:23 PM

$BCRX over 1 mill traded in the last 2 min for

0 · Reply

Ttubular Aug. 1 at 8:17 PM

$BCRX crazy volume in the last 10 min. Almost 8 mill shares traded today

1 · Reply

Market Cap	1.66B
Revenue (ttm)	450.71M
Net Income (ttm)	-88.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	65.12
Profit Margin	-19.72%
Debt to Equity Ratio	-1.81

Volume	7,971,100
Avg Vol	3,582,144
Day's Range	N/A - N/A
Shares Out	209.25M
Stochastic %K	5%
Beta	1.10
Analysts	Strong Sell
Price Target	$16.73